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“Eventually, everything connects.” 
 – Charles Eames

  
 
  
ABSTRACT
 
M i c r o R N A s  ( m i R N A s )  C O M P R I S E  a large family of small (~23 nucleotide in 
length), endogenous RNAs that regulate gene expression at the posttranscriptional level. 
Functional studies have indicated that miRNAs participate in the regulation of nearly all 
cellular processes investigated so far, including differentiation, apoptosis, and 
proliferation. Further, the deregulation of miRNA expression greatly contributes to 
human diseases, and is associated with many human pathologies, such as cancer. 
  
 The studies in this thesis have focused on miRNA expression and regulation in 
various forms of malignancies. Specifically, we wanted to provide mechanistic insights 
into the role of miRNAs in tumorigenesis. In parallel, we hoped to discover new 
therapeutic targets that could be exploited clinically to treat childhood and adult cancer. 
In the work presented, we describe the functional consequences of miRNA 
perturbations in three distinct neoplasias: (1) chronic lymphocytic leukemia (CLL), the 
second most common type of blood cancer in adults; (2) neuroblastoma (NB), an 
embryonal malignancy of the sympathetic nervous system that is derived from 
primordial neural crest cells and occurs almost exclusively in infants and young 
children; and, (3) basal cell carcinoma (BCC), a basal cell-derived malignancy of the 
epidermis, which ranks as the most commonly diagnosed human cancer among fair-
skinned individuals. 
  
 Our CLL studies revealed that the DLEU2 transcript functions as a regulatory host 
gene for the miRNAs miR-15a and miR-16-1. These miRNAs were shown to target the G1 
cyclins D1 and E1 for translational repression, resulting in a prominent cell cycle arrest. 
Further, ectopic expression of DLEU2 inhibited the colony-forming capacity of tumor 
cell lines, suggesting a tumor-suppressive function for miR-15a and miR-16-1. We also 
demonstrate that DLEU2 is transcriptionally regulated by the oncoprotein c-MYC, 
providing a novel mechanism by which MYC can regulate the G1 cyclins in a 
posttranscriptional manner. Functional loss of DLEU2 may thus constitute an important 
step in CLL tumorigenesis and various c-MYC-dependent cancers. 
  
  
  
 In our analysis of MYCN-amplified neuroblastoma (NB), we investigated the 
molecular consequences and functional outcome of abnormal miRNA regulation and 
discovered that miR-17~92 cluster-derived miRNAs potentiate the tumorigenic behavior 
of this childhood cancer. Importantly, we could show that miR-18a and miR-19a target 
and repress the expression of estrogen receptor-α (ESR1), a ligand-inducible 
transcription factor implicated in neuronal differentiation. We propose that ESR1 
represents a previously undescribed MYCN target in NB and demonstrate a unique 
oncogenic circuitry in which the repression of ESR1 through MYCN-regulated miRNAs 
may play a fundamental role in NB tumorigenesis. 
  
 Finally, based on our genome-wide miRNA expression analysis of a non-melanoma 
skin cancer, we found that the skin-specific miRNA, miR-203, is preferentially lost in 
BCC.  Functional analyses demonstrated that the inappropriate activation of the 
Hedgehog and MAPK pathways in BCCs may contribute to cancer progression via 
severely reduced expression of miR-203, which dramatically facilitates the misexpression 
of genes involved in the regulation of cell proliferation and cell cycle, including c-JUN 
and c-MYC. In this respect, miR-203 constitutes a ‘gatekeeper’ miRNA controlling 
keratinocyte proliferation. The molecular reconstitution of miR-203 could therefore 
serve as a novel therapeutic strategy in the treatment of BCC tumors. 
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1 .  INTRODUCTION
 
I N  T H E  L A S T  decade, the biology of ribobnucleic acid (RNA) has witnessed a 
transformation unmatched by any other area in medical research. The discovery that 
RNA molecules act as versatile regulators of eukaryotic gene expression has reshaped 
our understanding of gene regulation and function. At present, any transcript, 
regardless of coding potential, may have an intrinsic function as an RNA. Whether long 
or short, noncoding RNAs (ncRNAs) have been found to regulate some of the most 
important levels of genome function, including chromatin structure, transcription, RNA 
processing, RNA stability and translation.                                                                                                                        
 In 1986, Walter Gilbert proposed the RNA world hypothesis, a theory about the 
origin of life based on the view that the most critical event is the emergence of a self-
replicating molecule, a molecule that can both copy itself and mutate and, hence, evolve 
to more efficient copying (Gilbert, 1986). RNA is such a molecule. During the very early 
stages of life on Earth, proteins were not yet engaged in biochemical reactions and RNA 
carried out both the information storage task of genetic information and the full range 
of catalytic roles necessary in a very primitive self-replicating system.                                                                                          
 Despite this functional versatility, RNA was long considered a docile molecular 
entity, largely operating as an inert intermediary between gene and protein. However, 
the finding that most of the genomes of complex organisms are transcribed in a 
regulated fashion along with the discovery of several classes of regulatory, noncoding 
RNAs (including microRNAs) has challenged this assumption (Mercer et al., 2009). 
Recent advances have revealed unexpected diversity of function for various ncRNAs, 
suggesting that RNA has continued to evolve and expand alongside DNA and protein.                 
 The work presented in this thesis focuses on a particular class of small noncoding 
RNAs termed microRNAs, or miRNAs, and their functional role in developmental 
pathways and cancer etiology. 
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T H E  m i c r o R N A s
 
I N  B I O L O G Y ,  H E T E R O C H R O N Y  refers to changes, over evolutionary time, in the 
rate or timing of developmental events (Moss, 2007). Differences in the relative timing 
of developmental events have long been believed to be a major force in the evolution of 
morphology. Early attempts to identify heterochronic phenotypes in Caenorhabditis 
elegans (C. elegans) revealed a collection of genes that, when mutated, execute stage-
specific cell fates at inappropriately early or late time-points (Chalfie et al., 1981). These 
so-called ‘heterochronic’ genes were identified among a larger group of  lineage-
abnormal (lin) mutants, and revealed a developmental timing mechanism that functions 
independently of other types of developmental regulation, including growth, induction 
and differentiation (Moss, 2007).  
 Among the first heterochronic mutants to be described was lin-4. Mutations in lin-4 
caused the first larval stage (L1) to reiterate at later developmental stages (figure 1) 
(Chalfie et al., 1981). The converse phenotype was later observed for the lin-14 mutant, 
which arose spontaneously in a culture of lin-4 mutant animals. Omission of the L1 cell 
fates and premature development into the L2 stage are observed in worms that are 
deficient for lin-14 (Ambros and Horvitz, 1984). Following extensive mutagenenic 
analyses, it was realised that lin-4 encodes a pair of small untranslated RNAs measuring 
61 and 22 nucleotides (nt) in length (Lee et al., 1993). Surprisingly, these lin-4 RNAs had 
antisense complementarity to multiple sites of the 3’-untranslated region (3’UTR) of the 
lin-14 gene (Lee et al., 1993). lin-14, on the other hand, encodes a nuclear protein, 
downregulation of which at the end of L1 initiates the developmental progression into 
the second larval stage (L2) (Lee et al., 1993; Ruvkun and Giusto, 1989). In addition to a 
functional lin-4 gene, the negative regulation of the LIN-14 protein requires an intact 
3’UTR (Lee et al., 1993; Wightman et al., 1991).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The heterochronic phenotype of the lin-4 mutant in C.elegans. 
Worms with mutations in lin-4 do not develop normally and cell divisions 
characteristic of larval stage 1 (L1) reiterate throughout development.
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 Together, these findings led to the characterisation of a novel regulatory pathway in 
which lin-4 RNAs negatively regulate lin-14 translation by binding to its 3’UTR. The 
subsequent discovery that another temporally regulated 21 nt small RNA in C. elegans, 
let-7, was readily detected among phylogenetically distinct bilaterians indicated a more 
general role for small RNAs in developmental regulation (Pasquinelli et al., 2000). It was 
also established that several additional small RNAs with structural characteristics 
resembling lin-4 and let-7 were detectable throughout metazoan development (Lagos-
Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). However, unlike the lin-4 
and let-7  RNAs, which had been classified as short temporal RNAs (stRNAs) due to their 
common roles in controlling developmental timing, many of the newly cloned small 
RNAs did not display heterochronic features. Thus, the annotation stRNA was 
abandoned and replaced with the term microRNA (miRNA), to denote all small RNAs 
with similar features but unknown functions (Bartel, 2004).  
 Since their original discovery, miRNAs have been detected in all metazoans surveyed 
so far for their presence, including poriferans and cnidarians, and are even present in 
other distantly related eukaryotuc lineages, such as plants and algae (Grimson et al., 
2008). Hence, miRNAs constitute one of the most abundant classes of gene-regulatory 
molecules in the animal and plant branhces of eukaryota. 
 
 
microRNA Biogenesis 
m i R N A s  A R E  B R O A D L Y  defined as small (~23 nt in length), endogenous RNAs that 
play important gene-regulatory roles by pairing to the mRNAs of protein-coding genes 
to direct their posttranscriptional repression (Bartel, 2009). MiRNAs belong to a broad 
class of small RNAs, including endogenous small interfering RNAs (endo-siRNAs) 
(Reinhart and Bartel, 2002) and the Piwi-interacting RNAs (piRNAs) (Aravin et al., 
2007). Together, these RNAs act as sequence-specific guides in RNA silencing pathways. 
Processed from distinctive hairpin-shaped transcripts, miRNAs act as guide molecules in 
posttranscriptional processes that involve base-pairing with cognate messenger RNA 
(mRNA) targets, usually in the 3’ untranslated region (3’UTR).  
 Binding of a miRNA to the target mRNA typically leads to translational repression 
and/or mRNA destabilasation, although other types of regulation, including 
translational activation and heterochromatin formation, have been described 
(Filipowicz et al., 2008; Kim et al., 2008; Orom et al., 2008). At present, the number of 
confidently identified miRNAs has surpassed 110 in C.elegans, 140 in the fly Drosophila 
melanogaster and 400 in humans, corresponding to ~ 1–2% of the number of protein-
coding genes in these species (Bartel, 2009). Initial efforts based on computational 
methods estimated that more than one third of human genes appear to be conserved 
miRNA targets (Lewis et al., 2005), while recent estimates suggest that more than 60% 
of all human protein-coding genes are under selective pressure to maintain pairing to 
miRNAs (Friedman et al., 2009).  
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 With regard to their genomic organisation, a sizable portion (~40%) of miRNAs are 
present within introns of pre-mRNAs, providing a convenient mechanism for the 
coordinated expression of intron-embedded miRNAs and protein-encoding mRNAs 
(Bartel, 2004). Furthermore, most mammalian miRNA genes are clustered in the 
genome, allowing them to be transcribed simultaneously as polycistronic transcription 
units (Altuvia et al., 2005; Bartel, 2004). Intronic incorporation and genomic miRNA 
aggregation allows for miRNAs to employ existing functional promoter elements, 
eliminating the need for de novo assembly of transcriptional features, such as promoter-
enhancer sequences, transcriptional start sites (TSS), and transcription factor binding 
sites (TFBS) (Saini et al., 2007; Zhou et al., 2007). Although a majority of miRNA genes 
are transcribed by RNA polymerase II (Pol II) (Cai et al., 2004; Lee et al., 2004), a subset 
of miRNAs are processed  by RNA polymerase III (Pol III), including the dense cluster of 
human miRNAs interspersed among repetitive Alu elements on chromosome 19 
(Borchert et al., 2006). Both RNA polymerases are regulated differently and recognize 
specific promoter and terminator elements, facilitating a wide variety of regulatory 
options, thus allowing miRNA genes to be elaborately expressed in particular contexts 
and cell types.  
 
 
In the Nucleus 
M A T U R A T I O N  O F  m i R N A s  involves several sequential processing steps. In animals, 
canonical miRNA genes are transcribed by Pol II into primary miRNAs (pri-miRNAs) 
that are typically several kilobases (kb) long, 5’-capped, polyadenylated, and contain 
local stem-loop structures (Kim, 2005; Kim et al., 2009). These stem-loop structures 
serve as substrates for nuclear cleavage of the pri-miRNA by the Microprocessor 
complex, which contains the RNase III endonuclease Drosha and the cofactor DiGeorge 
syndrome critical region gene 8 (DGRC8) in humans (or Pasha in D. melanogaster and 
C. elegans) (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Lee et al., 2003). The 
two RNase domains of Drosha cleave the 5’ and 3’ arms of the pri-miRNA hairpin ~11 bp 
away from the single-stranded RNA–double-stranded RNA (ssRNA-dsRNA) junction 
with the aid of DGCR8, which stably interacts with the ssRNA segments and ~33 bp of 
the stem (Han et al., 2004; Han et al., 2006). This nuclear reaction liberates a ~60-70 nt 
stem-loop intermediate, known as the miRNA precursor (pre-miRNA) (Lee et al., 2002).  
 Drosha-mediated cleavage of the pri-miRNA occurs co-transcriptionally and precedes 
splicing of the protein-encoding or non-coding host RNA containing the miRNAs. 
Splicing is not influenced by Drosha-mediated cleavage, thereby ensuring both miRNA 
biogenesis and protein synthesis from a single primary transcript (Kim and Kim, 2007; 
Morlando et al., 2008). However, the inclusion of miRNA-resembling stem-loop 
structures in exonic regions of mRNAs may affect transcript stability. Drosha negatively 
regulates its co-factor  DGCR8 via two highly conserved hairpin structures in its 5’UTR 
and in the coding sequence near the start codon, which results in DGCR8 mRNA 
destabilisation following Drosha-mediated cleavage (Han et al., 2009).  
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 Additional observations support a functional role for miRNA–5’UTR/exonic 
interactions in conveying target-associated repression, implying that putative miRNA-
resembling stem-loop structures in non-3’UTR regions of mRNAs may serve as RNA 
control elements influencing mRNA stability (Duursma et al., 2008; Lee et al., 2009; 
Lytle et al., 2007). The participation of other, yet-to-be-described nucleases in this mode 
of mRNA metabolism are also thought to exist (Karginov et al., 2010). 
 In addition to canonical processing pathways, a subset of miRNAs mature following 
the completion of splicing. These miRNAs, termed mirtrons, derive from short introns 
and their biogenesis does not require Drosha processing (Berezikov et al., 2007; 
Okamura et al., 2007; Ruby et al., 2007). Such non-canonical small RNAs are produced 
when debranching of lariat-shaped introns results in the appropriate formation of a 
hairpin structure resembling a pre-miR. Additional 5’- or 3’-end exonucleolytic trimming 
of mirtron tails is occasionally required before these RNAs are suitable as substrates for 
nuclear export. Deletion of DGCR8 in mouse embryonic stems cells (mESC) has also 
revealed Microprocessor-independent, Dicer-dependent generation of small non-
mirtoronic RNAs from other non-coding RNA loci, such as the isoleucine transfer RNA 
(tRNA) gene, while Dicer-dependent processing of the small nucleolar RNA (snoRNA) 
ACA45 generates small RNAs with miRNA-like function (Babiarz et al., 2008; Ender et 
al., 2008). Evidently, multiple non-canonical pathways contribute to a substantial 
fraction of pre-miR abundance in mammalian cells through Drosha-independent 
pathways.  
 
 
In the Cytoplasm 
A F T E R  T H E  C O M P L E T I O N  of nuclear processing, pre-miRNAs are exported into to the 
cytoplasm by Exportin-5, (EXP5), a nuclear transport receptor, in complex with Ran-
GTP (Lund et al., 2004). Originally assumed to be a minor export factor of tRNAs, EXP5 
predominantly mediates nuclear export of both short-hairpin RNAs (shRNA) and pre-
miRs (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2005). EXP5 binds cooperatively 
to double-stranded RNA (dsRNA) independently of sequence or loop structure 
(Gwizdek et al., 2003; Zeng and Cullen, 2004), thus ensuring the export of only correctly 
processed small RNAs with a characteristic stem-motif of 14-16 bp and short 3’ overhangs 
(Lund and Dahlberg, 2006). 
 Once in the cytoplasm, pre-miRs are cleaved near the terminal loop by the RNase III 
endonuclease Dicer, releasing ~22 nt miRNA duplexes with ~2 nt 3’ overhangs at either 
end. This cleavage is essential for miRNA processing and has been described in many 
organisms, including C. elegans, D. melanogaster, and mammals (Bernstein et al., 2001; 
Grishok et al., 2001; Hutvagner et al., 2001; Ketting et al., 2001). In humans, Dicer 
interacts with the dsRNA-binding domain proteins TAR RNA-binding protein (TRBP) 
and protein activator of PKR (PACT) and the core component Argonaute proteins 1-4 
(Ago 1-4) (Gregory et al., 2005; Lee et al., 2006). Together, these proteins contribute to 
miRNA-programmed RNA-induced silencing complex (miRISC) assembly by forming a 
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RISC-loading complex (RLC). Although TBRP and PACT are not essential for Dicer-
mediated cleavage of pre-miRNAs, RLC formation is facilitated in their presence 
(Chendrimada et al., 2005; Lee et al., 2006).  
 After Dicer-mediated cleavage, Dicer and its interactors TRBP and PACT dissociate 
from the miRNA duplex. The two miRNA strands are then separated and one of the 
strands associates with an Ago protein within RISC, where it acts as a guide to repress 
target messages. Strand selection is determined by inherent features of the miRNA 
duplex, including thermodynamic asymmetry/stability (Khvorova et al., 2003; Schwarz 
et al., 2003). Typically, the strand whose 5’ end is less stably base-paired will be more 
frequently chosen as the functional guide strand. The other strand (the passenger strand 
or miRNA*) is presumed to be excluded from miRISC incorporation and subsequently 
degraded (Carthew and Sontheimer, 2009). However, recent deep-sequencing efforts 
have revealed that a large number of miRNA* strands can be appreciably detected in 
Ago complexes, and are in large part functional. Differential sorting of miRNA duplex 
strands correlates with specific mismatches at positions 9 and 10 of the mature miRNA 
and the 5’ nucleotide identity of the strand (Czech et al., 2009; Okamura et al., 2009; 
Okamura et al., 2008). In addition, relative levels of the miRNA/miRNA* strands vary 
widely across tissues (Hu et al., 2009; Landgraf et al., 2007). Together, these findings 
suggest that miRNA precursors can be bifunctional, with individual strands adopting 
different fates within small RNA pathways (figure 2). 
 
Figure 2. miRNA biogenesis and assembly into miRISC 
 
 Once a single strand has been selected, the miRNA acts as an adaptor for miRISC to 
specifically recognise and regulate particular mRNAs. With the exception of a few 
aforementioned examples, miRNA-binding sites in metazoan mRNAs lie in the 3’UTR 
and are present in multiple copies. Most miRNAs base pair imperfectly with their 
targets, following a set of rules determined by experimental and bioinformatic analyses 
(Brennecke et al., 2005b; Doench and Sharp, 2004; Grimson et al., 2007; Lewis et al., 
2005; Nielsen et al., 2007). The most stringent requirement of miRNAs base-pairing to 
their targets is a contiguous and perfectly matched Watson-Crick interaction of miRNA 
nucleotides 2-7, representing the seed region. Other molecular determinants, such as 
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pairing to the 3’ region of the miRNA (3’-supplementary and 3’-compensatory pairing) 
and UTR accessibility, are known to enhance binding specificity and affinity (Bartel, 
2009). Recently, the miRNA targeting code expanded to include functional sites with 
centered pairing, to describe target sites that lack both perfect seed pairing and 3’-
compensatory sites and instead have 11-12 contiguous Watson-Crick pairs to the center 
of the miRNA (Shin et al., 2010).  
 The degree of miRNA-mRNA complementarity will generally dictate the outcome of 
the miRNA-mRNA interaction. Perfect complementarity allows Ago-catalysed cleavage 
of the mRNA strand, although very few examples of miRNA-dependent cleavage have 
been observed in mammals (Meister et al., 2004; Yekta et al., 2004). More commonly, 
metazoan miRNAs direct translational repression, mRNA destabilisation, or a 
combination of both (Filipowicz et al., 2008). The mechanisms by which miRISC 
regulates translation are not entirely clear; i.e. whether repression occurs at the 
translational initiation or postinitiation step of mRNA maturation. Several models have 
been proposed, including repression of initiation at the 7-methylguanosine (m7G) cap 
stage, miRISC-dependent obstruction of translationally competent ribosomes at the 
AUG start codon, or premature ribosome dissociation from mRNAs at the 
postinititation stage (i.e. the elongation phase) (Carthew and Sontheimer, 2009). The 
mechanisms associated with mRNA destabilisation, however, are proposed to operate 
though deadenylation, decapping, and exonucleolytic digestion of the miRNA-bound 
mRNA, resulting in a significant reduction in mRNA abundance (Bagga et al., 2005; 
Behm-Ansmant et al., 2006; Giraldez et al., 2006). This reaction requires Ago, GW182, 
and the cellular decapping and deadenylation machinery (Behm-Ansmant et al., 2006). 
Although the molecular principles underlying the preferred mode of posttranscriptional 
repression remain elusive, it has been suggested that the number, type and position of 
mismatches in the miRNA/mRNA duplex play an important role in triggering 
degradation or translational arrest (Aleman et al., 2007). Suffice to say, miRNAs affect 
protein production at many different levels with distinct biological outcomes. 
 
 
The Biological Functions of miRNAs 
S I N C E  T H E  D I S C O V E R Y  that lin-4 and let-7 play critical roles in the timing of larval 
development in C. elegans, miRNAs have been implicated in a bewildering array of 
biological settings, and the importance of miRNAs in select developmental processes in 
model organisms is indisputable. In particular, miRNAs appear to partake in pathways 
associated with cell fate determination and differentiation, thereby contributing to the 
specification of many cell types.  Global attenuation of miRNA biogenesis through 
genetic manipulation of Dicer has revealed several clues to miRNA function in 
developmental contexts. Dicer loss of function results in profound phenotypic defects in 
both zebrafish and mice, emphasising the importance of the miRNA pathway in 
vertebrate development. However, by in large, early stages of development progress 
normally in Dicer –/–embryos. For example, zebrafish embryos lacking Dicer develop 
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without profound defects until maternal stores of Dicer are depleted, approximately 
eight days post-fertilisation (Wienholds et al., 2003). Even Dicer-deficient zebrafish 
embryos lacking maternal Dicer (MZdicer mutants) exhibit only mild phenotypic 
perturbations within the first 24 hours of development (Giraldez et al., 2005), suggesting 
that miRNAs are not essential for cell fate determination and early patterning, but 
provide critical functions at subsequent steps in embryonic development. Like zebrafish 
MZdicer mutants, mouse embryos lacking Dicer do not display gross morphological 
defects before the onset of gastrulation (~embryonic day 7.5), again pointing to an 
important role for miRNAs in later stages of development (Bernstein et al., 2003).   
 This notion is further supported by the temporal and spatial expression patterns of  
conserved vertebrate miRNAs in zebrafish embryos, as well as other model systems, 
including mouse and chicken (figure 3)  (Ason et al., 2006; Darnell et al., 2006; 
Wienholds et al., 2005). For example, miR-196 and miR-10 genes of various vertebrates 
reside in the homeobox (HOX) gene clusters and function at later stages of vertebrate 
development. Like the HOX genes, miR-196 and miR-10 are colinearly expressed in a 
spatial and temporal manner along the anterior-posterior body axis during development 
and preferentially target HOX mRNAs (Yekta et al., 2008).  In mouse embryous, both 
miRNA families have highest expression in the neural tube and lower expression levels 
in the trunk mesoderm, with ill-defined anterior limits and broad posterior expression 
through the tail (Mansfield et al., 2004). The observed expression domains of these 
miRNA families are in agreement with the patterns that are expected on the basis of 
their locations within the HOX clusters.  
                             
               A     B         
      
Figure 3. A miRNA catalog of the 
developing chicken embryo 
identified by a deep sequencing 
approach. (A) The self-organising 
tree algorithm (SOTA) diagram on 
the left illustrates miRNA kinetics 
in the chicken embryo at 
embryonic day E4 (left lane), E5 
(middle lane), and E6 (right lane). 
The total number of sequence 
reads increased over time, 
demonstrating significant changes 
in relative miRNA abundance 
between the three embryonic small 
RNA libraries. (B) A neural-tube 
enriched miRNA expression profile 
at embryonic day E5.5. Note the 
high levels of the miR-196 and 
miR-10 family members, consistent with their colinear expression and regulation of Hox mRNAs. 
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 Although the expression patterns among orthologous miRNAs may vary between 
species, these studies demonstrate that many miRNAs are expressed with precise tissue 
specificity late (rather than early) in development, presumably due to their participation 
in tissue-specific functions and lineage-promoting effects. Indeed, recent studies have 
shown that the unique modalities by which specific miRNAs exert their widespread 
function in various developmental settings depend on both the timing and pattern of 
their expression, as well as the repertoire of co-expressed targets.  
 
 
miRNAs, Transcription Factors, and Regulatory Networks 
G I V E N  T H A T  M O R E  than half of mammalian mRNAs are under selective pressure to 
maintain base-pairing interactions with miRNAs (Friedman et al., 2009), most biological 
processes are likely to be influenced by miRNA function. With such a broad impact on 
gene regulation, miRNAs have rapidly emerged as one of the most abundant gene 
regulatory factors in multicellular genomes. In this respect, miRNAs share many 
regulatory characteristics with transcription factors (TF), which suggests that miRNAs 
and TFs share a common regulatory logic (Hobert, 2004).  
 Transcription factors exert their effects by directly (or indirectly) binding DNA at 
specific genomic loci to control the transcription of nearby genes. In doing so, 
transcription factors can influence cell fate decisions, functioning as key switches by 
regulating gene expression programs on a genome-wide level. A single transcription 
factor can thus, through positively or negatively regulating transcription of numerous 
genes, execute entire cellular or tissue-level programs. To this end, gene repression has 
surfaced as an important theme in shaping cell-specific gene regulatory programs, 
especially in developmental contexts (Bilodeau et al., 2009; Boyer et al., 2006; Hobert, 
2004).  
 However, like miRNAs, TFs rarely operate single-handedly; rather, sets of 
combinatorially expressed TFs and miRNAs act together to precisely delineate 
individual cell types and fates (Hobert, 2008; Marson et al., 2008). Cooperativity 
therefore provides a mechanistic basis for describing the overall output of combinatorial 
expression patterns of TFs and miRNAs. These combinatorial codes are in turn 
controlled by more upstream events, such as signaling cascades, which play an integral 
part in regulatory transactions in cells (Weake and Workman, 2010). Developmental 
processes can therefore be considered as a succession of hierarchically acting regulatory 
states (Davidson et al., 2002).  Consequently, transcriptional regulatory programs have 
been placed into well-defined regulatory networks that are characterised by small sets of 
recurring network motifs that endow the system with specific properties such as signal 
amplification, dampening, and oscillation (Alon, 2007). As trans-acting factors, TFs and 
miRNAs frequently associate in small-scale gene regulatory networks with defined 
topology (Martinez et al., 2008; Tsang et al., 2007). Similar to the network motifs shared 
by transcription factors, miRNA network motifs are typically composed of feedforward 
and feedback loops (Herranz and Cohen, 2010). Thus, miRNA regulatory events 
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interface with known TF and signaling networks that control cell fate and 
differentiation, modulating their activity through positive and negative feedback loops 
to reinforce cellular decisions. 
 
  
Variability, Robustness, and Stochastic Gene Expression 
B I O L O G I C A L  S Y S T E M S  A R E  continuously challenged by an environment that is 
variable, yet developmental and physiological processes are remarkably stable, resulting 
in stereotyped outcomes (Hornstein and Shomron, 2006). Such variability, also referred 
to as ‘noise’, has multiple sources, including variations in the activity of individual genes, 
cell-to-cell variations in metabolic activity, or fluctuating levels of an external signal, and 
must be controlled in living systems in order to maintain phenotypic stability. Gene 
regulatory networks, involving feedforward and feedback loops, are particularly suited 
to control the effects of noise, by buffering its impact on gene expression (Raser and 
O'Shea, 2005).  
 The ways in which cells and organisms use noise and deal with can greatly influence 
cellular behavior and phenotypic consequences. By in large, developmental programs 
are deterministic; however, mechanisms have evolved to buffer stochastic fluctuations, 
thereby conferring robustness to gene regulatory networks (Hornstein and Shomron, 
2006). One form of noise management, termed canalisation, has been selected over the 
course of evolution to impart developmental pathways with high phenotypic 
reproducibility. However, some biological processes utilise noise to trigger stochastic 
developmental decisions (Losick and Desplan, 2008). As miRNAs are frequently 
embedded in network motifs, their function is often related  to the nature and topology 
of the network to which they belong, suggesting that they confer useful regulatory 
possibilities to facilitate network decision-making and biological outcomes (e.g. 
homeostasis, differentiation, and/or lineage specification). In some contexts, miRNAs 
act as binary switches to help repress target protein output to inconsequential levels 
while in other settings miRNAs act as rheostats to dampen (tune) protein output to 
more optimal levels (Bartel, 2009). The ways in which network motifs and miRNAs 
manage the impact of noise therefore differs from one biological process/circuit to 
another. 
 
 
C L A S S I C A L  S W I T C H  I N T E R A C T I O N S  shaped the initial paradigm of miRNA 
targeting, whereby miRNA induction turns off expression of a pre-existing target. In 
network language, these interactions are examples of  feedback (positive or negative) 
motifs (figure 4).  Initial examples of switch interactions include lin-4 targeting lin-14 and 
lin-28, and let-7 targeting of lin-41 (Bartel, 2009; Reinhart et al., 2000). The recent 
characterisation of D. melanogaster miR-14 has revealed a different type of regulatory 
switch that acts by limiting stochastic expression of its target, the ecdysone receptor 
(EcR). In Drosophila, the steroid hormone Ecdysone and its receptor EcR play a key role 
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in control of developmental timing. Pulses of Ecdysone followed by EcR activation 
trigger a complex hierarchy of gene expression programs that control the physiological 
and morphological changes involved in metamorphosis (Thummel, 1996, 2001). An 
important feature of this process is its all-or-none character, which depends on a 
positive feedback loop involving transcriptional autoregulation of EcR (Karim and 
Thummel, 1992; Koelle et al., 1991). Random transcription (noise) is a stochastic event 
that often occurs in bursts (Raj and van Oudenaarden, 2008). Random transcriptional 
fluctuations of EcR need to be limited to avoid a self-amplifying response. miR-14 acts 
directly to reduce EcR levels, and reciprocally, EcR negatively regulates miR-14, thereby 
keeping the circuit in balance. Upon hormonal induction, EcR will negatively regulate de 
novo transcription of miR-14 and residual miR-14 levels will eventually subside, 
permitting the cell to distinguish between sustained input of hormone-induced EcR 
activation and transcriptional fluctuations in EcR levels (Varghese and Cohen, 2007). 
Thus, while miR-14 prevents inappropriate transitions to occur during development due 
to noise, it constitutes a developmental switch that allows major transformations in 
gene expression programs when a certain threshold level is reached.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Examples of simple positive and negative feedback loops. 
miR-14 acts in a negative feedback loop modulating EcR activity. 
 
 
F A I L S A F E  I N T E R A C T I O N S  R E F E R  to switch interactions in which a miRNA is 
already present when the target is first expressed. For example, sense organ specification 
in the D. melanogaster peripheral nervous system is a stochastic event modulated by 
miR-9a, which inhibits the sporadic production of additional neuronal precursor cells 
(Li et al., 2006). Sense organ primordia are initially defined as small groups of cells that 
express a set of proneural basic helix–loop–helix (bHLH) transcription factors of the 
Hairy-E(spl) (HES) family. Definition of the proneural cluster at this level is 
deterministic, based on programmed control of gene expression, but fluctuations in the 
level of the transcription factor Senseless determines which cell adopts the sense organ 
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precursor (SOP) fate (Herranz and Cohen, 2010). The stochastic selection of a SOP cell 
leads to an increase in proneural gene expression, which feeds back to increase Senseless 
expression. Senseless also increases expression of the Notch ligand Delta, which in turn 
leads to increased Notch signaling activity in the adjacent cells. Notch activity represses 
proneural gene expression in these cells, and reinforces the advantage of the Senseless- 
and Delta-expressing cell toward becoming the SOP (Jafar-Nejad et al., 2003). As 
positive feedback loops are inherently labile, additional (failsafe) mechanisms are 
needed to ensure that random fluctuation in transcription factor levels does trigger 
positive feedback inappropriately. 
  In this biological context, miR-9a sets a threshold that Senseless transcription must 
overcome in order to activate the Senseless–proneural feedback loop (Li et al., 2006). 
Importantly, miR-9a expression is under proneural gene control and miR-9a levels are at 
first uniform in the proneural cluster. Following stochastic selection of the SOP, 
Senseless activity increases proneural gene expression with concurrent reduction of 
miR-9a expression. However, miR-9a levels remain high in the surrounding cells, where 
proneural gene activity is kept low through Notch activity. The opposing regulation of 
Senseless and miR-9a is an integral element of the switch. The transcriptional feedback 
system is triggered by random fluctuations in gene expression, and miR-9a helps to 
reinforce selection of the SOP cell, thereby bestowing the noise-dependent switch with a 
failsafe, functionally redundant layer of control (Herranz and Cohen, 2010). 
 
 
F E E D F O R W A R D  R E G U A L T I O N  R E P R E S E N T S  the second type of network motifs. 
Feedforward loops (FFLs )have been described in a multitude of gene systems, from 
bacteria and yeast to mammals (Alon, 2007). Feedforward motifs consist of three 
components: an upstream regulator (TF) and two targets (e.g. a miRNA and a target 
gene). Assuming that each of the three regulatory interactions can be either positive or 
negative, there are eight possible structural types of FFL (Alon, 2007). Further, 
depending on the nature of the relationships between the components, FFLs can be 
classified as being either coherent or incoherent (Mangan and Alon, 2003). In a coherent 
FFL, the miRNA is induced, directly or indirectly, by a TF that repress the target, i.e. the 
posttranscriptional repression by the miRNA is synergistic with transcriptional 
inhibition of the same target. In this regard, the coherent FFL can be considered failsafe, 
as it enhances the fidelity of a genetic program by ensuring that aberrant transcripts do 
not give rise to consequential amounts of protein. Reciprocally, the TF may activate 
target transcription and repress miRNA production, thereby removing miRNA-mediated 
constraints on target gene expression. The impact of coherent FFLs has recently been 
described in both developmental and oncogenic contexts. For example, miR-7 has been 
implicated in two coherent feedforward motifs involved in the specification of 
photoreceptor cell in the Drosophila eye (Li et al., 2009). Likewise, let-7 belongs to a 
feedforward motif underlying oncogenic transformation in response to inflammatory 
signals (Iliopoulos et al., 2009).  
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 Incoherent FFLs are less intuitive and have different properties than coherent FFLs, 
but are just as common as coherent types (Tsang et al., 2007). Incoherent FFLs are 
particularly suited as triggers for oscillatory systems, enabling more customised 
expression in different cell types as well as more uniform expression within each cell 
type. In this scenario, the miRNA is important in fine-tuning the expression level of the 
target gene. One well-studied example of an incoherent FFL involves c-MYC, miR-17~92 
cluster-derived miRNAs and cell cycle progression (O'Donnell et al., 2005). c-MYC 
transcriptionally induces the expression of E2F1, which in turn regulates an array of cell 
cycle genes. This is accompanied by the concomitant, c-MYC-dependent induction of 
miR-17 and miR-20a, which repress E2F1. The overall outcome of these interactions 
results in the precise pulse of c-MYC-induced E2F1 expression needed for optimal cell 
cycle progression (figure 5).  
 
 
 
 
 
 
 
 
 
 
Figure 5. Feedforward motifs where X regulates Z directly and indirectly through regulation of Y. 
Coherent motifs have the direct and indirect paths from X acting on the target Z in the same 
direction. Incoherent motifs have the opposite outcomes for the two paths. miR-2o and miR-17 
act in an incoherent feedforward motif. c-MYC activates E2F directly while repressing its 
expression posttranscriptionally via miR-20 and miR-17. This opposing activity sets a precise E2F 
expression level, and thus promts cell cycle progression. 
 
 
Network Buffering and Genetic Canalisation 
A L T H O U G H  m i R N A s  A N D  TFs are interconnected in shared regulatory motifs and 
these regulatory events appear quite similar, their individual importance as regulatory 
factors is different. Thorough genetic analyses in unicellular and multicellular organisms 
has firmly demonstrated the importance of TFs in controlling development and 
homeostasis (Davidson et al., 2002; Kamath et al., 2003). Likewise, the genetic 
elimination of Dicer can produce striking phenotypes, especially defects in later 
developmental events (Levy et al., 2010; Zehir et al., 2010). However, many miRNAs, even 
the most highly conserved, can be eliminated individually without causing obvious 
phenotypes (Miska et al., 2007). In fact, the deletion of 95 C. elegans miRNA loci 
revealed that less than 10% of miRNA knockouts results in clear developmental or 
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morphological defects (Miska et al., 2007). In contrast, recent RNA interference (RNAi) 
loss-of-function analysis show that a substantially higher proportion of genes required 
for viability in C. elegans are enriched for TFs, associated with developmental processes, 
and cause easily discernable phenotypes (Fraser et al., 2000; Kamath et al., 2003). This 
implies that many miRNAs may be functionally redundant, yet it is difficult to reconcile 
their extreme conservation with redundancy. Moreover, gene-knockout phenotypes in 
flies and vertebrates can be very subtle, and are commonly masked by the considerable 
derepression of only a few conserved targets (Baek et al., 2008; Nakahara et al., 2005; 
Selbach et al., 2008).  
 Large-scale proteomic analysis following miR-223 disruption in vivo indicated that 
very few messages in a biologically accurate setting were repressed by more than 50% 
(Baek et al., 2008). Instead, miR-223 had more modest effects on its endogenous targets 
(including conserved targets), with individual sites reducing protein output by ~30% 
(Bartel, 2009). Several reasons may account for these observations. First, the nature of 
specific miRNA:target interactions may play an important role. Messages with multiple 
conserved sites and particularly favorable sites are more likely to represent highly 
responsive miRNA:target interactions, resulting in substantial target repression. This has 
been illustrated by numerous examples, including the lin-4:lin-14 interaction, the let-
7:Hmga2 interaction and  the miR-18:ESR1 interaction (Lee et al., 1993; Loven et al.; Mayr 
et al., 2007; Wightman et al., 1993). However, these types of interactions represent only a 
minority of preferentially conserved targets, and modest repression appears to be the 
more common regulatory outcome of a miRNA:target interaction. With more than 90% 
of conserved miRNA:target  interactions involving only a single site to the miRNA, most 
of these targets would be expected to be downregulated by less than 50% (Bartel, 2009). 
 In addition, since most messages with a conserved site to one miRNA have at least 
one other conserved site to an unrelated miRNA, disruption of multiple miRNA:target 
interaction sites might be necessary before the derepression generated has overt 
consequences (Bartel, 2009). Mild phenotypes may also be the result of the vast 
functional diversity of many miRNA targets. Often, ~2-fold protein fluctuations can be 
tolerated, as evidenced by the rarity of haploinsufficeint phenotypes, even when the 
targets themselves are regulatory proteins (e.g. TFs). This phenomenon, known as 
network buffering, may constitute an additional function for miRNAs.  
 Many regulatory interactions, including many miRNA:target interactions, fall within 
complex regulatory networks with bifurcating pathways and feedback control that 
enable accurate response despite a defective node in the network. With this ability to 
buffer the effects of losing a node, such networks must be perturbed elsewhere before 
the lost miRNA interaction has discernable phenotypic consequences (Bartel, 2009). In 
line with their role as genetic buffers, mounting evidence suggests that miRNAs may 
serve as canalising genes, i.e. that miRNA regulatory networks evolved under natural 
selection in order to stabilise phenotypes and decrease the variability of specific traits 
(Hornstein and Shomron, 2006). For example, the muscle-specific miRNA miR-1 is 
conserved in sequence and expression pattern throughout the bilaterian lineage. On this 
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basis, miR-1 was presumed to play an important role muscle patterning or 
differentiation. However, the knockout of miR-1 in D. melanogaster resulted in 
functional muscles that develop normally (Sokol and Ambros, 2005). Only at the onset 
of rapid larval growth phase does the pheontypic muscle crisis emerge, suggesting that 
miR-1 confers robustness to the identity and physiology of muscle cells (Brennecke et al., 
2005a). In this setting, miR-1 is dispensable for muscle differentiation but upon growth 
stress conditions the lack of miR-1-mediated target interactions causes discernable 
phenotypic consequences and decanalisation of the network (Hornstein and Shomron, 
2006).  
 
 
miRNAs Operate As Pleiotropic RNAs with Diverse Function 
W I T H  S U C H  S E E M I N G L Y  diverse modes of regulation and action, it is difficult to 
assign a generic role to miRNA function. However, a few basic assertions can be made 
based on the hitherto mentioned examples: (1) miRNAs participate in regulatory 
networks driven by TF and signaling events that control cell fate and differentiation. 
miRNAs modulate these events through positive and negative feedback loops to 
facilitate cellular decisions and reinforce biological outcomes; (2) miRNAs can act as 
binary switches to help repress target protein output to inconsequential levels or as 
rheostats to dampen (tune) protein output to more optimal levels. This, in turn, 
depends on the nature and topology of the network to which the miRNA belongs, and 
the nature of specific miRNA:target interactions in a particular cell type; and (3) 
miRNAs are essential for the normal development of animals. However, since miRNAs 
tend to have highly tissue-specific expression patterns during later stages of 
development, miRNAs are most likely controlling particular aspects of terminal 
differentiation programs of individual cell types, i.e. miRNAs do not govern early 
cell/tissue fate establishment but are critical in later differentiation steps and in the 
maintenance of tissue identity and integrity. 
 It is noteworthy to mention that while many miRNAs participate in tissue 
development and identity, several vertebrate miRNAs partake in cell-autonomous 
processes associated with cellular physiology. For example, the liver-specific miR-122 
plays an important role in cholesterol biosynthesis and fatty acid metabolism (Esau et 
al., 2006; Krutzfeldt et al., 2005). Murine miR-375 is specifically expressed in pancreatic 
islet β-cells and regulates glucose-stimulated insulin secretion and exocytosis through 
its interactions with Myotrophin. Restricted predominantly to keratinocytes, miR-203 
functions as a switch between proliferative and terminally differentiating compartments 
in vertebrate skin (Yi et al., 2008), while the miR-23 family members miR-23a and miR-
23b play a more general role in controlling glutamine metabolism reactive oxygen 
species (ROS) homeostasis (Gao et al., 2009). Given the high number of miRNA genes 
identified so far, their regulation and diverse expression patterns along with the 
overwhelming abundance of putative miRNA:target interactions, it is not surprising that 
miRNAs have been implicated in a broad spectrum of diseases, including cancer. 
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CANCER
T H E  T E R M  C A N C E R  encompasses more than 100 distinct diseases with diverse risk 
factors and epidemiology which originate from most of the cell types and organs of the 
human body and which are characterized by relatively unrestrained proliferation of cells 
that can invade beyond normal tissue boundaries and metastasize to distant organs 
(Stratton et al., 2009). With such an extensive range of origins and features, it is difficult 
to pinpoint a single attribute common to all cancers. Nonetheless, cancer can be broadly 
described as a genetic, disease-causing accumulation of mutations which arises through 
a multistep, evolutionary process occurring among somatic cell populations within the 
microenvironments provided by the tissues of a multicellular organism (Hanahan and 
Weinberg, 2000; Vogelstein and Kinzler, 1993). In this respect, malignancy can be 
considered both a penalty and a potent selection force in the evolution of 
multicellularity. On one hand, normal physiology requires large, continuously renewing 
cellular populations, while on the other hand every cell division risks the initiation of 
evolutionary events leading to a fatal malignancy.  
 Analogous to Darwinian evolution of species, cancer development resembles 
evolution on the somatic level, characterised by the continuous acquisition of heritable 
genetic variation in individual cells by random mutation and natural selection acting on 
the resultant phenotypic diversity (Stratton et al., 2009). In fact, carcinogenesis can be 
considered as two evolutionary competing processes: (1) potential cancer-forming cells 
evolving with adaptations to overcome the tumor suppression mechanisms of the host 
organism; and (2) the organism evolving strategies to reduce the probability of death 
from cancer prior to and during reproductive maturity (Gatenby et al., 2010). 
Constraining the emergence of cancer has thus become an evolutionary imperative in 
metazoans, especially in large, long-lived organisms with tissues that continuously 
regenerate (Lowe et al., 2004).  
 Cell growth, cell division, and the programmed elimination of cells (apoptosis) are 
tightly controlled processes which act to benefit multicellular organisms in response to 
environmental cues. The precise regulation of these processes is a requisite to the proper 
functioning of the organism. Occasionally, a single cell acquires a set of sufficiently 
advantageous mutations that allows it to proliferate autonomously, invade tissues and 
metastasize. However, no single mutation is sufficient to cause cancer; rather cancer 
results from various genetic and epigenetic alterations (i.e. heritable changes in gene 
expression that are not accompanied by changes in DNA sequence) that eventually 
confer cells with an ability to escape normal regulation. Most (if not all) malignant 
tumors acquire the same set of functional capabilities, commonly referred to as the 
hallmarks of cancer. These include (1) self-sufficiency in growth signals; (2) insensitivity 
to antigrowth signals; (3) evasion of apoptosis; (4) limitless replicative potential; (5) 
sustained angiogenesis; and (6) tissue invasion and metastasis (Hanahan and Weinberg, 
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2000). Once endowed with these properties, a neoplastic cell rapidly gains a proliferative 
advantage and eventually outcompetes its surroundings in order to thrive and grow 
(Nowell, 1976).  
 
 
Adult Cancer 
W H A T E V E R  T H E  R O U T E S  or mechanistic strategies needed to reach malignancy may 
be, the progressive conversion of normal cells into cancer cells is fundamentally a 
function of three aspects: inheritance, the environment, and changes over time 
(evolution). First, with respect to inheritance, most attributes of tumor development can 
be explained by genetic alterations of primary DNA sequence. While some mutations 
are inherited through the germline, others appear de novo in somatic cells and are 
restricted to the neoplastic lineage. Additionally, epigenetic information, encoded as 
binomial patterns of DNA methylation, also participates in cancer progression (Feinberg 
and Tycko, 2004; Jones and Baylin, 2007). As a heritable disease, cancer constitutes the 
propagation of genetic end epigenetic information, either inherited or transmitted, on a 
cellular and multicellular level. Second, epidemiologic data has demonstrated a clear 
association between cancer development and environmental factors like smoking, diet, 
and radiation (Vineis and Berwick, 2006). Numerous studies have substantiated the 
causal relationship between environmental mutagens and the initiation of cancer (Soto 
and Sonnenschein, 2010). Finally, cancer is, by in large, an age-related disease that 
develops over long periods of time. Cancer incidence is known to increase dramatically 
with age (Vogelstein and Kinzler, 1993) and virtually all individuals over the age of 50 
carry some kind of in situ carcinoma (Folkman and Kalluri, 2004). Genes and mutations 
thus evolve in dynamic interaction with the surrounding environment, and cancer 
development is best described as an evolutionary process within the organism (Gatenby 
et al., 2010). Accordingly, cancers in adults result from a multistep process and often 
progress over many years or decades.  
 
 
Childhood Cancer 
T H I S  I S  I N  contrast to tumors that develop during childhood (0-15 years of age), which 
set them apart from adult (solid) tumors. Childhood tumors, including neuroblastomas, 
Wilm’s tumor, retinoblastomas, lymphomas, and CNS malignancies, are fundamentally 
developmental disorders; the nature of the progenitor cells from which these tumors 
arise allows these cancers to develop with fewer defects in cell regulatory processes than 
adult cancers. Much of the cellular behavior (e.g. spontaneous regression) which 
typically characterises pediatric cancers derives from their developmental nature. 
Further, processes which typify adult cancers (proliferation, survival, self-renewal, and 
migration), are all aspects of normal developmental programs. Essentially, cancers that 
arise during prenatal and postnatal development are driven by normal growth and 
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differentiation-promoting mechanisms associated with organogenesis, tissue growth, 
and maturation (Scotting et al., 2005).  
 The relationship between childhood cancer development and the onset of 
organogenesis is supported by the fact that the age-specific pattern of these tumors 
often coincides with the periods of maximum growth of the related normal tissue. 
Neuroblastoma, Wilms’ tumor, and hepatoblastoma occur in children younger than four 
years of age, whereas bone tumors, germ-cell tumors, and Hodgkin’s disease occur 
predominantly in adolescents (Altekruse et al., 2009). The immature tissue environment 
represents an additional feature intimately linked to the onset and maintenance of 
perinatal cancers. In developing tissues, the progeny of most dividing cells are primarily 
more dividing cells, providing a favorable context for errors in DNA replication and a 
microenvironment in which proliferation is favored over differentiation (Scotting et al., 
2005). Perturbations in the microenvironment can therefore accelerate uncontrolled cell 
growth and survival of immature cells that retain the ability to undergo high levels of 
proliferation and migration.  
 Likewise, the changing environment of the growing host can partially explain the 
biological and clinical heterogeneity observed in childhood cancers, but not in adult 
cancers, such as spontaneous regression. It should also be noted that many childhood 
tumors, with the exception of high-risk neuroblastoma, do not necessarily follow the 
dogmatic route of transformation during tumor progression, such as chromosomal 
instability, aneuploidy, or amplification of genetic damage. For example, infant 
teratomas generally show no signs of gross genetic damage and childhood cancer cells 
generally have fewer cytogenic defects than adult tumors (Oosterhuis and Looijenga, 
2005). With fewer aberrations, childhood malignancies offer more therapeutic avenues 
and respond more readily to biologically targeted interventions (e.g. retinoic acid 
treatment for neuroblastoma and acute myeloid leukemia). In summary, childhood 
tumors represent a unique category of neoplasms that deviate from adult-onset cancers, 
both in their cell biology and their tissue microenvironment. 
 
 
Tumor Suppressor Genes and Oncogenes 
T H E  T H R E E  F E A T U R E S  of cancer development mentioned in the earlier section 
(inheritance, environment, and time) have been consolidated in a linear model, which 
has long served as a standard paradigm of carcinogenesis (Arends, 2000; Fearon and 
Vogelstein, 1990). Central to this model are the two categories of genes that are affected 
by mutational events during tumor initiation and progression: oncogenes and tumor 
suppressor genes (TSG) (Vogelstein and Kinzler, 1993).  
 Oncogenes are classified as genes that have acquired gain-of-function mutations (or 
exhibit abnormal expression levels) and are capable of promoting cancer. Under normal 
circumstances, oncogenes are referred to as proto-oncogenes and function to regulate 
cell growth and differentiation. Proto-oncogenes are frequently involved in signal 
transduction pathways, and play important roles in the execution of mitogenic signals. 
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Upon inappropriate activation however, a proto-oncogene (or its product) may, in the 
presence of a selective environment, promote cell autonomy and thereby support 
transformation and tumorigenesis. Examples of proto-oncogenes include c-MYC, GLI, 
and RAS.  
 Tumor suppressor genes, on the other hand, represent gene products that can 
function to counteract the onset of malignancy. Since the cancer-preventive effects of 
TSGs usually require the presence of only a single functional gene, prototypic tumor 
suppressor genes are recessive, requiring “two-hit” inactivation of both alleles, a concept 
formulated by Alfred Knudson in 1971 following studies of inherited and sporadic cases 
of retinoblastoma (Knudson, 1971; Sherr, 2004). TSGs are commonly inactivated (via 
deletions, mutations, or epigenetically) in human tumors and participate in a multitude 
of critical cellular processes, including apoptosis, senescence, and DNA repair. 
Accordingly, the involvement of TSGs in cell cycle checkpoint control, mitogenic 
signaling pathways, protein turnover, DNA damage, hypoxia, and other stress responses 
reflects the broad spectrum of cell-autonomous processes that can be deregulated in 
cancer cells (Sherr, 2004). Bona fide TSGs include p53, PTEN, and RB, all of which are 
frequently deregulated in a vast majority of cancers (Harris and Hollstein, 1993; Li et al., 
1997).  
 Since its formulation, the ‘standard model’ has embodied the efforts of cancer 
research in its pursuit to describe the multifaceted nature of cancer development. These 
efforts have primarily focused on identifying the genetic and/or epigentic alterations of 
protein coding elements in the genome. With the realisation that noncoding RNAs, 
notably miRNAs, play functional roles in developmental and cancer-associated 
processes, cancer should now be regarded as a complex genetic disease involving 
countless abnormalities in both coding and non-coding genes.  
 
 
The MYC Oncoprotein 
C O M P A R A B L E  T O  T H E  p53 gene and its protein product (which are mutated in more 
than 50% of all human cancers), the prevalence of MYC deregulation in human cancers 
is staggering (Levine et al., 2004). No category of tumor, whether it be adult or pediatric, 
solid or hematological, has managed to entirely elude MYC, and the broad spectrum of 
neoplasms associated with MYC perturbations reflects its central role in the onset and 
progression of tumorigenesis (Nesbit et al., 1999).  
 Originally identified as the cellular homologue of the avian acute leukemic (MC29) 
viral transforming sequence, c-myc was the first cellular oncogene shown to be activated 
through retroviral promoter insertion (Hayward et al., 1981). Unlike the other proto-
oncogenes discovered during this pioneering period of cancer research (e.g. RAS), MYC 
activation was not the result of mutations in its coding sequence. Instead, novel 
mechanisms, including insertional mutagenesis, chromosomal translocations, and gene 
amplification, were found to deregulate MYC (and other oncogenes), providing new 
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paradigms for the genetic basis of cancer. The function of MYC, in both normal and 
pathological settings, has been intensively examined ever since, and the MYC gene 
family ranks among the most exhaustively studied groups of genes in biology (Eilers and 
Eisenman, 2008).  
 Briefly, the MYC family of proto-oncogenes encodes a number of transcription factors 
(c-MYC, MYCN, and L-MYC) that heterodimerise with the cofactor MYC-associated 
protein X (MAX), bind DNA, and activate a substantial portion of coding and non-
coding elements in the genome (Cawley et al., 2004; Fernandez et al., 2003). 
Functionally, Myc-activated genes serve to stimulate cell growth by initiating ribosome 
biogenesis, protein synthesis, metabolism, and cell cycle progression. Simultaneously, 
genes involved in cell-cycle arrest, cell adhesion, and cell-cell communication are 
inhibited. The manner in which gene expression is restricted upon MYC activation is 
less clear but at least one mechanism has been reported to involve MYC:MAX-
dependent displacement of co-factor recruitment to genes bound by the zinc finger 
transcriptional activator Miz-1 (Herold et al., 2002; Staller et al., 2001). Furthermore, 
MYC:MAX complexes are counteracted by the MXD family proteins, which anatgonise 
MYC function by sequestering accessible MAX and, as heterodimers (MNT:MAX or 
MAD:MAX), promote repression at genomic loci otherwise activated by MYC (Eilers and 
Eisenman, 2008).  
 Taken together, MYC posses the capacity to both activate (directly) genes that 
stimulate growth and deactivate (directly and/or indirectly) genes that abrogate cell 
cycle inhibition. Thus, by responding to both external and internal cues, MYC proteins 
modulate and influence a myriad of cellular processes, including proliferation, growth, 
apoptosis, metabolism, and differentiation, all of which are frequently deregulated in 
MYC-dependent cancers (Albihn et al., 2010). 
 
 
miRNAs In Cancer 
T H E  E A R L I E S T  C O M P R E H E N S I V E  evidence connecting miRNAs to cancer came 
from the observation that miRNA genes are greatly enriched in genomic loci known to 
undergo chromosomal rearrangements, deletion, and amplification (Calin et al., 2004). 
More direct proof was attained when high-throughput technologies enabled the 
detection of miRNA expression on a genome-wide level, which revealed that abnormal 
expression of miRNAs was a common feature of all tumors investigated (Lu et al., 2005; 
Volinia et al., 2006). Interestingly, these studies reported a global downregulation of 
miRNA expression in cancer cells, with the exception of a few, highly overexpressed 
miRNA family members (e.g. members of the miR-17~92 family). These data were 
consistent with the hypothesis that in mammals, as in C. elegans, miRNAs can function 
to prevent cell division and drive terminal differentiation.  
 Indeed, global miRNA expression patterns reflect the state of cellular differentiation 
in tumors, highlighting the potential of miRNA profiling in cancer diagnosis. An 
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extension of this hypothesis suggested that differential expression levels of certain 
miRNAs might play a causal role in the generation or maintenance of tumors (Lu et al., 
2005). The belief that miRNAs dysfunction can be a causative event in cancer 
pathogenesis has very recently been addressed in transgenic mouse models (Costinean 
et al., 2006; Dorsett et al., 2008; Klein et al., 2010; Medina et al., 2010). These studies 
clearly demonstrate that, similar to prototypic protein-coding oncogenes and TSGs, the 
misexpression of select miRNAs (even the misexpression of a single miRNA) is sufficient 
promote and maintain tumor growth and survival in vivo. Below, I have highlighted 
examples of miRNAs with tumor-suppressive activity and miRNAs with oncogenic 
properties, paying special attention to the cancer forms which I have focused on during 
my PhD studies. 
 
 
Tumor Suppressor miRNAs 
T H E  F I R S T  m i R N A s  demonstrated to have altered expression in tumor cells and 
causatively linked to cancer were miR-15a and miR-16-1 (Calin et al., 2002b). These 
miRNAs are clustered on chromosome 13 within the larger consensus minimal deleted 
region (MDR) 13q14, a region that is deleted in more than half of B-cell chronic 
lymphocyte leukemias (CLL) (Dohner et al., 2000). CLL represents the most common B 
cell-derived malignancy in the adult population, accounting for ~30% of all leukemias 
(Redaelli et al., 2004). An insidious disease with a chronic course, CLL is charcterised by 
the clonal expansion of proliferating, neoplastic CD5+ B lymphocytes (Chiorazzi and 
Ferrarini, 2003).  
 The course of the disease is variable and while some patients with CLL have a normal 
life span (indolent CLL), others present with more aggressive disease and die within five 
years after diagnosis (Rozman and Montserrat, 1995). In cases of disease progression, 
overexpression of c-MYC, deletions of the Rb gene, and mutations of the p53 have been 
reported (Rozman and Montserrat, 1995). Nevertheless, the genetic cause of CLL 
remains unknown and its pathogenesis is obscure. On the one hand, CLL is a 
morphologically homogenous tumor, while on the other, it represents a lymphoma with 
high clinical heterogeneity. However, there are a few molecular and clinical features 
which unify CLLs. These include the presence or absence of somatically mutated 
immunoglobulin variable region (IgV) genes (i.e. pre-germinal versus post-germinal 
center leukemia), a set of different recurring chromosomal alterations, mainly deletions 
(including 13q14), and the accumulation of malignant CD5+ B lymphocytes. In view of 
these characteristics, CLL might result from a multistep process, beginning with an 
antigen-driven polyclonal expansion of CD5+ B lymphocytes that, in a mutationally 
conducive setting, would eventually transform into monoclonal proliferation. 
  The accumulation of malignant cells in CLL has long been considered a consequence 
of an inherent apoptosis defect, rather than excessive proliferation, since CLL cells 
frequently overexpress the antiapoptotic protein Bcl-2. In fact, it was suggested that loss 
of function of miR-15a and miR-16-1 promotes enhanced expression of Bcl-2 and thus 
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abnormal survival of CLL cells (Cimmino et al., 2005). Lately, these concepts have been 
challenged. For example, CLLs express significantly shorter telomeres than aged-
matched B cells as a result of more frequent cell divisions (Damle et al., 2004). 
Furthermore, by measuring CLL cell kinetics in vivo, the production rate of leukemic 
cells in patients has been estimated to fall in the range of 109 – 1012 per day (Messmer et 
al., 2004), reflecting the high proliferative capacity of CLL cells. Importantly, our careful 
analyses of miR-15a/16-1 function (see Paper I) strongly suggest a role in cell cycle 
progression, a finding that was recently corroborated in vivo using a miR-15a/16-1 
transgenic mouse model (Klein et al., 2010). Other studies have reached the same 
conclusion in miR-15a/16-1-deficient cancers, including non-small cell lung cancer and 
prostate cancer (Bandi et al., 2009; Bonci et al., 2008). A more thorough analysis of 
Paper I and its implications are provided in the Results and Discussion section. 
 
 m i R - 2 0 3 ,  A  miRNA preferentially expressed in the suprabasal layer of skin, represents 
another bona-fide tumor suppressor miRNA. Early insights into its function revealed 
that miR-203 acts as a switch between proliferation and differentiation during 
embryonic skin development (Yi et al., 2008). By altering the embryonic, spatiotemporal 
expression pattern of miR-203 in vivo, it was found that premature expression of miR-
203 promoted epidermal differentiation by restricting the proliferative potential of 
targeted basal stem cells and inducing early cell cycle exit. When miR-203 was inhibited 
chemically using antagomiR technology (Krutzfeldt et al., 2005) in neonatal mice, 
antagomiR-203-treated dorsal skin showed clear elevations in epidermal proliferation 
and atypical expansion of p63 expression, an essential regulator of stem cell 
maintenance in epithelial tissue (Yi et al., 2008).  
 These findings point to an antiproliferative function for miR-203 in the skin and, as 
evidenced by its tumor-suppressing effects in select hematopoietic malignancies, 
suggests that loss of miR-203 expression and/or function may promote tumorigenesis 
(Bueno et al., 2008). As miR-203 is preferentially expressed in the skin, it is highly 
probable that significant disruption of miR-203 levels in the epidermis may contribute to 
various types of skin disorders, such as skin cancer. Paper III in this thesis demonstrates 
that severely reduced expression of miR-203 is a typical feature of basal cell carcinoma 
(BCC), resulting in a deregulation of critical genes in the Hedgehog (Hh) pathway and 
subsequent hyperproliferation of transformed keratinocytes.  
 BCCs, the most common malignancy among persons of European ancestry, are 
keratinocyte tumors and appear as slow-growing, elevated lesions on sun-exposed skin 
(Epstein, 2008). Exposure to ultraviolet radiation is generally accepted as the major 
cause of BCCs, although a  rare, familial variant of BCCs frequently occurs in basal cell 
nevus syndrome (BCNS) patients (commonly referred to as Gorlin syndrome) (Rubin et 
al., 2005). Despite the high incidence of BCCs among Caucasians, these tumors rarely 
metastasize; nevertheless, they can cause significant tissue destruction by tissue 
invasion.  
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 Central to both sporadic and familial BCCs is the inappropriate activation of the Hh 
signaling pathway, originally identified as a determinant of segment polarity in D. 
melanogaster (Nusslein-Volhard and Wieschaus, 1980). Deregulation of the HH pathway 
is also common to other tumors, such as medulloblastoma and rahbdomyosarcoma 
(Taipale and Beachy, 2001). Briefly, secreted Sonic hedgehog (SHH) protein binds the 
TSG patched homologue 1 (PTCH1), relieving its suppression of smoothened (SMO). 
SMO signaling culminates in the activation of the Gli family of transcription factors 
(GLI1, GLI2, and GLI3), which execute SHH-induced signals. As the constituents of the 
HH pathway are intimately associated with proliferative responses in target cells, 
proteins belonging to the HH network are frequently misexpressed in BCCs (including 
loss-of-function mutations of PTCH1 and gain-of-function mutations of SMO). Our work 
presented in Paper III of this thesis establishes that miR-203 plays an intricate role in 
fine-tuning key components of the HH network. By assuring the precise protein output 
of downstream effectors (e.g. c-MYC and c-JUN) of Hh signaling and other mitogenic 
pathways, miR-203 constitutes a ‘gatekeeper’ miRNA controlling keratinocyte 
proliferation. 
 
 
Oncogenic miRNAs 
I N  2 0 0 5 ,  T W O  seminal papers published in Nature provided the first demonstration 
that miRNAs are functionally integrated into oncogenic pathways and participate in 
cancer development (He et al., 2005; O'Donnell et al., 2005). Analyses of a genomic locus 
(13q31.3) frequently amplified in various lymphomas and solid tumors revealed that 
C13orf25, the only gene found to be upregulated within this amplicon, was a non-coding 
miRNA polycistron encoding six miRNAs: miR-17, miR-18a, mi-19a, miR-19b-1, miR-20a, 
and miR-92a. Collectively referred to as the miR-17~92 cluster, enforced expression of 
these miRNAs hematopoietic stem cells were found to dramatically accelerate the onset 
of B cell lymphoma in the Eµ-myc transgenic mouse model, providing direct evidence 
that the miR-17~92 cluster has oncogenic activity in vivo (He et al., 2005). In the same 
issue of Nature, O’Donnell et al. reported that the miR-17~92 cluster is transcriptionally 
activated by the transcription factor c-MYC (O'Donnell et al., 2005). Since then, 
expression profiling studies have revealed a widespread overexpression of miR-17~92-
derived miRNAs in several tumor subtypes, including cancers of the breast, colon, brain, 
prostate, lung, and nervous system (Volinia et al., 2006). The second paper included in 
this thesis (Paper II) demonstrates the molecular outcome of abnormal miR-17~92 
expression in MYCN amplified neuroblastoma (NB), an embryonal tumor derived from 
the sympathetic nervous system (SNS).  
 NB is an embryonal tumor derived from the immature cells of the developing SNS 
and represents the most common cancer of infancy that occurs during the first year of 
life (Altekruse et al., 2009). NB tumors account for more than 7% of malignancies in 
patients younger than 15 years and approximately 15% of all pediatric oncology deaths 
(Maris et al., 2007). The clinical hallmark of neuroblastoma is heterogeneity, with the 
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likelihood of tumor progression varying widely according to anatomic stage and age at 
diagnosis. Although great improvements in disease outcome have been observed in 
certain well-defined subsets of patients, the outcome for children with high-risk NB 
remains poor, with long-term survival still less than 40% (Maris et al., 2007). In general, 
children diagnosed before 1 year of age and/or with localized disease are curable with 
surgery and little or no adjuvant therapy. Intriguingly, some of these tumors undergo 
spontaneous regression or differentiate into benign ganglionueromas (Matthay, 1999), 
referred to as stage 4S (S=special) disease. This striking clinical phenotype, which occurs 
in about 5% of cases, was first described by  D’Angio and colleagues, who observed that 
infants with small, localised primary tumors accompanied by metastases to liver, skin, or 
bone marrow frequently experience spontaneously regression (D'Angio et al., 1971). In 
contrast, older children often have extensive hematogenous metastases at diagnosis, and 
the majority die from disease progression despite intensive multimodal therapy.  
 The clinical diversity observed in patients correlates closely with several molecular 
biologic features of neuroblastoma. Activating, germ-line mutations in the anaplastic 
lymphoma kinase (ALK) oncogene were recently discovered in hereditary NB, and 
occasionally occur in sporadic NBs (Chen et al., 2008; George et al., 2008; Janoueix-
Lerosey et al., 2008; Mosse et al., 2008). The genetic events underlying sporadic 
neuroblastoma are less clear, although enrichments of single-nucleotide-polymorphisms 
(SNP) within the non-coding RNA FLJ22536 and the DNA-repair ligase BARD1 have been 
detected in patients with progressing disease (Capasso et al., 2009; Maris et al., 2008). 
The biological variables that define advanced stage disease include 1p36 deletion (with 
subsequent loss of the p53-regulated tumor-suppressor miR-34a), allelic loss of 11q, 
17q22-qter gain. In addition, amplification of the MYCN locus, present in ~20 to 30% of 
all cases, represents the most important genetic aberration, and is strongly related to 
poor clinical diagnosis (Maris et al., 2007).  
 Originally cloned in 1983 by identifying an amplified DNA sequence with partial 
homology to the c-MYC gene, MYCN amplification is strongly associated with rapid 
disease progression and low event-free survival (Brodeur, 2003; Schwab et al., 1983). 
From a pathway perspective, poor outcome neuroblastomas (including all MYCN-
amplified cases) exhibit elevated signaling through the MYC transcriptional network (c-
MYC, MYCN, and L-MYC target genes), along with low expression of lineage marker 
genes relating to late neuronal differentiation. Additionally, these gene expression traits 
were not only present in high-risk tumors, but also in patients with tumors initially 
diagnosed as low or intermediate risk that ultimately had an adverse outcome (Fredlund 
et al., 2008). In agreement with these findings, NB tumors with high MYC pathway 
activity also display specific miRNA gene signatures, including elevated expression levels 
of miRNAs belonging to the miR-17~92 cluster (Mestdagh et al., 2010).  
Our findings in Paper II suggest that specific expression changes in miR-17~92 cluster-
derived miRNAs may promote tumorigenic behavior of MYCN-amplified NB, the 
consequences of which are discussed in further detail in the following sections. 
 
   25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
2 .  AIMS
 
 
T H E  O V E R A L L  P U R P O S E  of this thesis was to explore the role of miRNAs in cancer 
in order to gain a more complete molecular understanding of the mechanisms 
underlying select childhood and adult malignancies. More specifically, this thesis aimed 
to: 
 
•  Characterise the regulation and function of the miR-15a/miR-16-1 host 
transcript DLEU2 and examine its role in tumor development, with particular 
emphasis on CLL (Paper I) 
 
•  Investigate the molecular consequences and functional outcome of abnormal 
miRNA transcription in MYCN-amplified NB (Paper II) 
 
•  Identify and elucidate the mechanism(s) by which abnormal miRNA 
expression in the epidermis may contribute to carcinogenesis of the skin and 
BCC tumor formation (Paper III)   
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3 .  RESULTS AND DISCUSSION
 
 
P A P E R  I .  
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the 
cell cycle inhibitory microRNAs miR-15a and miR-16-1 
 
I N  T H E I R  E F F O R T S  to clone a tumor suppressor gene at the 13q14 locus, Calin and 
coworkers were the first to show a causal link between miRNAs and cancer when they 
discovered that miR-15a and miR-16-1 reside in region commonly deleted in CLL.  
Specifically, they claimed that the 13q14 MDR in CLL includes miR-15a and miR-16-1 and 
occurs in 70% of all CLLs (Calin et al., 2002a). This is in contrast to a recent expression 
profiling study which demonstrated that only 11% (6 of 56 samples) of all CLL cases 
analysed had exceedingly low expression of miR-15a/miR-16-1 (Fulci et al., 2007). 
Furthermore, only three of these six patients showed biallelic loss of 13q14 (Fulci et al., 
2007), suggesting that alternative mechanisms contribute to miR-15a/miR-16-1 loss-of-
function in CLL. Germline mutations affecting pri-miR-15a/16-1 processing have been 
detected, but represented only a trivial fraction of patients analysed (2 of 75 CLL cases) 
and must therefore be considered a rare event (Calin et al., 2005). A similar finding has 
been reported in New Zeeland Black (NZB) mice that spontaneously develop a 
lymphoprolifertaive disorder highly reminiscent of CLL. These mice carry a syntenic 
point mutation in the 3’ flanking region of miR-16-1, resulting in decreased expression of 
miR-16 (Raveche et al., 2007). While biallelic loss and germline mutations negatively 
impact miR-15a/16-1 expression levels, these genetic perturbations do not account for all 
cases of miR-15a and miR-16-1 dysregulation in CLL. Moreover, breakpoint analyses of 
the 13q14 MDR in CLL consistently demonstrate that the miR-15a and miR-16-1 genes are 
frequently retained following deletion (Lerner et al., 2009; Liu et al., 1997). Instead, the 
refined 13q14 MDR involves the deletion of portions of DLEU1 and DLEU2, both of which 
are non-coding transcripts oriented in a sense/antisense fashion. Given that DLEU2, in 
contrast to DLEU1, is evolutionarily conserved (as are miR-15a and miR-16-1 positioned 
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intronically in DLEU2), it seems more plausible that DLEU2 represents the candidate 
tumor suppressor targeted by deletions and/or deregulation in CLL. In Paper I, we set 
out to investigate the regulation and function of the miR-15a/miR-16-1 host transcript 
DLEU2 and examine its role in CLL tumorigenesis. 
 As mentioned previously, most mammalian miRNA genes are clustered in the 
genome, allowing them to be transcribed simultaneously as polycistronic transcription 
units (Altuvia et al., 2005; Bartel, 2004). In addition, intronic incorporation and genomic 
miRNA aggregation allows for miRNAs to employ existing functional promoter 
elements. To determine if DLEU2 functions as a bicistronic host gene for miR-15a and 
miR-16-1, we assessed if the maturation of DLEU2 RNA was Drosha-dependent using 
RNAi. Knockdown of Drosha caused a significant accumulation of partially spliced 
DLEU2, yet did not affect the maturation of fully spliced DLEU2, suggesting that DLEU2 
transcripts are normally processed by Drosha in order to liberate functional miRNAs.  
 To further assess the regulatory features of DLUE2, we decided to investigate the role 
of both DLEU2 promoters and additionally assess the relevance of putative regulatory 
units just upstream of miR-15a/miR-16-1. As a recent report had demonstrated that MYC 
transcriptionally represses a substantial portion of miRNAs, including miR-15a and miR-
16-1 (Chang et al., 2008), we decided to test if reduction of  miR-15a/miR-16-1 expression 
was associated with concomitant DLEU2 downregulation. Using a doxycycline-regulated 
model system in which MYC expression can be turned off (Schuhmacher et al., 1999), we 
found that both miR-15a/miR-16-1 and DLEU2 expression levels increased in the absence 
of Myc. Further, our chromatin immuniprecipitation (ChIP) assays implied that reduced 
expression of DLEU2 is the result of direct Myc-mediated transcriptional binding of the 
two alternative DLEU2 promoters. In contrast, no binding was detected to any of the 
loci downstream of the first two DLEU2 exons, including the most conserved region 
immediately upstream of miR-15-a/miR-16-1. These findings conclude that DLEU2 
functions as a host gene for miR-15-a/miR-16. 
 Next, we wanted to analyse the function of miR-15-a/miR-16-1. In order to assess the 
tumor-suppressive effects of DLEU2, we performed colony formation assays in 
osteosarcoma (U2OS) and breast adenocarcinoma (MCF-7) cells. To this end, we cloned 
the miR-15-a/miR-16-containing DLEU2 transcript into a cytomegalovirus promoter 
(CMV)-driven expression vector. As expected, transfection of the DLEU2 plasmid 
resulted in the rapid upregulation of miR-15a and miR-16-1 in several cell lines, 
demonstrating that proper miRNA processing occurs after vector expression. We also 
generated a deletion mutant, DLEU2-ΔMIR that lacks miR-15a and miR-16-1. Ectopic 
expression of DLEU2 led to an ~80% decrease in colony number as compared to both 
mock- and DLEU2-ΔMIR-transfected cells. In parallel, DNA histogram analysis 
performed on HEK293 and U2OS cells transfected with DLEU2 showed a clear G1 arrest, 
suggesting an antiproliferative as opposed to an antiapoptotic effect. G1 arrest in DLEU2 
expressing cells was accompanied by hypophosphorylation of the Rb protein, further 
indicating that cell cycle entry was abrogated. 
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 Although it was initially reported that miR-15-a and miR-16-1 target the anti-
apoptotic gene bcl-2 (Cimmino et al., 2005), others have reported that  miR-15-a/miR-16-
1 function to inhibit cell cycle progression (Huang et al., 2007; Linsley et al., 2007), a 
notion that was recently confirmed in vivo using a miR-15a/16-1 transgenic mouse model 
(Klein et al., 2010). Using the PicTar and miRBase algorithms, we searched for putative 
miR-15-a/miR-16-1 targets and identified Cyclin D1 and Cyclin E1 as high confidence 
predictions. Transfection of DLEU2 into several different cell lines resulted in prominent 
downregulation of Cyclin D1 and Cyclin E1 on protein level. RT-PCR and cyclohexamide 
chase analysis established that the DLEU2-mediated repression of the G1-related cyclin 
proteins was not the result of a decreased mRNA levels or increased cyclin protein 
turnover. DLEU2-ΔMIR-transfected cells did not show protein abundance alterations of 
Cyclin D1 and Cyclin E1. Importantly, luciferase reporter assays established that the 
DLEU2-mediated repression of Cyclin D1 and Cyclin E1 was dependent on the 3’UTRs of 
these targets. 
 Taken together, this study delineated a functional role of the miR-15a/miR-16-1 host 
transcript DLEU2. The identification of DLEU2 as a regulatory host gene of these 
miRNAs elucidates how CLL deletions with miR-15a/16-1 retention may still result in 
their functional loss. The refined 13q14 MDR suggest that that loss of the promoters (and 
perhaps the first exons of DLEU2) result in the functional loss of these miRNAs. This 
notion is supported by the absence of miR-16-1 expression in CLL case 4 that retains 
miR-15a/miR-16-1 at the genomic level while deleting both alternative DLEU2 promoters 
(Figure 1). We also show that DLEU2 is negatively regulated by MYC, providing yet 
another mechanism by which DLEU2 may be deregulated in CLL and other cancers, 
some of which are Myc-dependent (Bonci et al., 2008). These data also demonstrate how 
activation of MYC can lead to the induction of multiple G1 cyclins in a 
posttranscriptional manner. The exact molecular features relating to miR-15a and miR-
16-1 interactions during cell cycle dynamics remain to be addressed. Their constitutive 
expression across the cell cycle phases (unpublished data) suggests that miR-15a and 
miR-16-1 may act as an additional regulatory layer to ensure both the precise expression 
of G1 cyclins levels during G0/G1-S transition and to reduce potentially harmful leaky 
expression of these cyclins in later cell cycle phases.  
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P A P E R  I I .  
MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and 
neuronal differentiation in human neuroblastoma 
 
N E U R O B L A S T O M A  H A S  L O N G  been considered a clinical enigma (Brodeur, 2003), 
owing to the incredibly diverse and often dramatic clinical behavior of NB tumors. NB 
accounts for disproportionate morbidity and mortality among childhood cancers while 
conversely representing the cancer with the highest incidence of spontaneous regression 
and complete tumor involution (Maris, 2010). While low risk and intermediate risk 
patients have a very high chance of survival, the outcome for children with high-risk NB 
remains poor, with long-term survival still less than 40% (Maris et al., 2007). A common 
feature of high-risk NB is MYCN amplification, which occurs in ~20% of primary NB 
tumors and is strongly correlated with advanced stage disease and treatment failure 
(Maris et al., 2007). While 1p36 deletions have been shown to precede MYCN 
amplification,  the mechanisms underlying MYCN-mediated NB progression are poorly 
understood. In Paper II, we wanted to gain further insights into the molecular processes 
associated MYCN-amplified NB, with specific emphasis on deregulated miRNA 
expression patterns and downstream targets. This, we hoped, would advance our 
understanding of MYCN-amplified NB and uncover novel pathways that could serve as 
clinical alternatives in NB disease management. 
 To begin, we employed a genome-wide miRNA expression array in order to identify 
MYCN-regulated miRNAs, using Tet21N NB cells with doxycycline-inducible MYCN 
expression. Our analyses revealed consistent ~2-fold overexpression of several MYC-
associated miRNAs previously identified,  including miRNAs from the oncogenic miR-
17∼92 cluster (e.g. miR-17, miR-18a, and miR-19a) and its paralogs on chromosome 7 and 
chromosome X (He et al., 2005; O'Donnell et al., 2005). We also noticed a robust 
decrease of miRNA expression in MYCN expressing cells, many of which exert tumor-
suppressive functions in various cancers (Croce, 2009). Further, our chromatin 
immuniprecipitation (ChIP) assays confirmed that MYCN:MAX associated with 
canonical E-box sequences upstream of all polycistronic miRNA units assayed, resulting 
in the transcriptional activation of miR-17∼92 cluster-derived miRNAs and its paralogs. 
 Next, we wanted to analyse the function of a subset of the miRNAs identified in our 
screen. It had previously been reported that overexpression of the miR-17∼92 cluster 
strongly augments NB tumorigenesis both in vitro and in vivo (Fontana et al., 2008).  
While the oncogenic contribution of miR-17 and miR-20a in relation to NB was 
described in this paper, the biological significance of other miRNAs residing in the miR-
17∼92 polycistron (including miR-18a and miR-19a) was not addressed. We therefore 
decided to interrogate miR-18a and miR-19a function in MYCN-amplified NB cells using 
miRNA-specific inhibitors followed by fluorescence-activated cell sorting (FACS) 
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analysis. These initial experiments conclusively demonstrated that miR-18a and miR-19a 
affect cell cycle progression. To further extend this finding, we employed lentiviral 
constructs encoding specific antisense miRNA sequences designed to target miR-18a and 
miR-19a function. Long-term inhibition of miR-18a resulted in a  dramatic phenotype, 
characterised by both morphological and biochemical differentiation, while the miR-19a 
knockdown was more difficult to assess. Nevertheless, our results suggested that  
miR-18a (and to a lesser degree miR-19a) provide MYCN-amplified cells with a 
proliferative advantage by deregulating messages linked to cell cycle progression and 
differentiation.  
 Using the Using the PicTar and Targetscan algorithms, we identified several genes 
downstream miR-18a and miR-19a that are involved in neural and cancer-associated 
processes (such as ROBO2, ATXN1, CCND2, and ESR1). A literature survey provided the 
first evidence that estrogen receptor-α (ESR1) could potentially account for the 
phenotype we observed in our miRNA knockdown experiments. In 1993, Ma and 
colleagues described the direct involvement of activated ESR1 in a series of 
morphological and biochemical changes that lead the transfected cells toward a 
differentiated state (Ma et al., 1993). Unintentionally, the authors used the MYCN-
amplified cell line SK-N-BE, which, by virtue of its MYCN amplification, expresses high 
levels of miR-18a and miR-19a, potentially leading to the aberrant repression of 
endogenous ESR1. Importantly, upon ligand-dependent activation, ectopic ESR1 in the 
genetically engineered NB cell line SK-N-E3 resulted in growth arrest (Ma et al., 1993). 
This led us to hypothesise that MYCN-regulated miRNAs might disrupt estrogen 
signaling sensitivity in cells derived from SNS precursors through deregulation of ESR1, 
thereby preventing the normal induction of neuroblast differentiation.  
 To experimentally assess this idea, we first used luciferase reporter assays to 
demonstrate that miR-18a and miR-19a repress ESR1 expression through miRNA-binding 
elements in its 3’UTR. Western blot and quantitative PCR (qPCR) analyses of MCF-7 
cells (which express high levels of endogenous ESR1) transfected with miR-18a and miR-
19a mimic oligonucleotides confirmed that these miRNAs also target endogenous ESR1. 
Next, to reaffirm Ma’s original work, we used lentiviral constructs expressing ESR1 cDNA 
and transduced SK-N-BE(2) cells. Upon lentiviral reconstitution of ESR1,  we observed 
cell cycle arrest and morphological changes indicative of differentiation.  
In addition, we were able to demonstrate ESR1 expression in human fetal sympathetic 
ganglia, suggesting that ESR1 plays an important role during the development of the 
sympathetic nervous system. Finally, our Kaplan-Meier survival analyses of 251 NB 
patients indicate that ESR1-positive NBs are associated with a favorable disease outcome.  
 In summary, we have uncovered a novel mechanism by which miRNA-mediated 
deregulation of ESR1 expression potentiates tumorigenesis in human neuroblastoma. On 
a far more fundamental level of neurobiology,  the demonstration of ESR1 expression in 
human fetal sympathetic ganglia suggests that ESR1 may act as a key constituent in the 
specification/diversification of the neural crest-derived sympatho-adrenal (SA) lineage.  
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The importance of estrogen and its receptors during neural development is 
recapitulated in embryonic neuronal stem cells, which undergo differentiation in 
response to estradiol exposure (Brannvall et al., 2002) Analyses of ESR1 expression 
during peripheral nervous system development in chicken embryos show ESR1-
immunoreactivity in the dorsal root ganglia (DRG) at cervical, thoracic and lumbo-
sacral levels, as well as in the sympathetic ganglia and primary spinal motoneurons (Cui 
and Goldstein, 2000). Interestingly, it has been shown that ESR1 potentiates mRNA 
expression of the tyrosine kinase receptor TrkA using a cancer cell line derived from a 
pheochromocytoma (PC12 cells) of the rat adrenal medulla (Sohrabji et al., 1994a; 
Sohrabji et al., 1994b). TrkA is the high affinity catalytic receptor for the neurotrophin 
(NGF) and mediates the multiple effects of NGF, which includes neuronal 
differentiation. Both undifferentiated (naïve to NGF) and NGF-exposed, differentiated 
PC12 cells (which resemble the sympathetic neuron phenotype) express ESR1 mRNA. 
While naive cells express very low levels of ESR1 mRNA, NGF elicits a significant 
increase in ESR1 mRNA. As in sensory neurons, NGF-mediated increases in ESR1 
expression resulted a ~3-fold upregulation of trkA mRNA (Toran-Allerand, 1996).  
 The cooperative interaction between ESR1, the neurotrophins and their receptors 
could be of great significance to the onset and progression of high-risk, MYCN-amplified 
NB. High levels of TrkA expression are correlated with younger age, lower stage, and 
absence of MYCN amplification. Furthermore, TrkA expression is highly correlated with 
favorable disease outcome (Brodeur, 2003). Thus, ESR1-positive NBs may represent a 
potential subgroup of tumors amenable to estrogen treatment, providing a means to 
force these tumors into spontaneous regression. Likewise, inhibition of miR-18a may 
represent a promising therapeutic opportunity for MYCN-amplified NB patients. 
 
 
P A P E R  I I I .  
miR-203 functions as a bona fide tumor suppressor microRNA in basal cell 
carcinoma 
 
B A S A L  C E L L  C A R C I N O M A  (BCC) is the most common type of malignant cancer in 
fair-skinned individuals. Common to both sporadic and familial BCCs is the 
inappropriate activation of the Hedgehog (Hh) signaling pathway, which plays a central 
role in the pathogenesis of BCC tumors, as well as medulloblastoma (MB) (Wicking et 
al., 1999). In sporadic BCCs, 10% show SMO gain-of-function mutations while ~70% of 
BCC tumors exhibit inactivating mutations in at least one allele of PTCH1 (Epstein, 
2008). Several murine models support the concept that aberrant Hh pathway activation 
is sufficient to drive development of BCCs or BCC-like tumors, including mice with 
constitutive or conditional overexpression of  GLI1 or of GLI2, activating SMO 
mutations, or PTCH1 haploinsufficiency (Aszterbaum et al., 1999; Grachtchouk et al., 
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2000; Nilsson et al., 2000; Xie et al., 1998). To date, all investigations on BCC tumor 
onset and development have focused on the mutations and/or expression of protein-
coding genes, and although several advances have been made, a comprehensive 
molecular description detailing BCC pathogenesis is still lacking. To this end, we set out 
to investigate the role of miRNA deregulation in BCC tumors. 
 To explore the potential involvement of miRNAs in basal cell carcinoma, we 
performed the first comprehensive, genome-wide analysis of miRNA expression in 
human healthy skin and BCCs. Unsupervised hierarchical clustering based on miRNA 
expression clearly separated BCC tumor samples from healthy skin, and most miRNAs 
with significant differential expression were suppressed in BCC. These findings suggest 
that the altered expression of miRNA has a role in the pathogenesis of BCC and enforces 
the observation that global downregulation of miRNA expression is a common feature of 
solid tumors (Lu et al., 2005). Of all miRNAs assayed, miR-203 showed the greatest 
decrease (~5-fold) in expression in BCC when compared to healthy skin, a finding which 
was further validated in a lager set of healthy and BCC samples. Expression analyses 
using in situ hybridization with specific locked nucleic acid (LNA) probes demonstrated 
that miR-203 was preferentially expressed in the suprabasal layers of healthy skin, 
almost in a gradient-like fashion, while BCC tumors consistently lacked miR-203 
expression.  
 Next, we wanted to explore the potential association between miR-203 
downregulation and the activation of the Hedgehog pathway. Quantitative real-time 
PCR results showed that both PTCH1 and GLI1 were significantly overexpressed 
(p<0.001) in BCC tumors as compared with healthy skin, in accordance with previously 
published data. Further, correlation analysis showed a significant negative correlation 
between miR-203 expression and GLI1, as well as between miR-203 and PTCH1, 
suggesting that  a loss-of-function of miR-203 may be associated with aberrant 
Hedgehog signaling in BCC.  
 Our next aim was to elucidate the potential mechanisms and/or pathways 
accounting for miR-203 suppression in BCC. Previous signal transduction analyses 
indicated that miR-203 is regulated by the PKC/AP-1 pathway and suppressed by growth 
factors, such as KGF and EGF in keratinocytes (Sonkoly et al., 2010). In BCC, EGFR has 
been shown to synergize with Hedgehog/GLI in oncogenic transformation via activation 
of the MEK/ERK/JUN pathway (Schnidar et al., 2009). Therefore, we set out to further 
explore the role of the EGFR signaling pathway in the regulation of miR-203. By 
measuring miR-203 expression in primary human keratinocytes treated with inhibitors 
of EGFR, MEK1/2, JNK, or Akt in combination with EGF or DMSO alone, we were able to 
determine that the EGFR-MAPK signaling pathway represses miR-203 expression, 
indicating that this pathway may negatively regulate miR-203 levels in BCC. 
 A bioinformatic search for putative miR-203 targets identified several genes in the 
MEK/ERK/JUN pathway, including c-JUN, as well as the Hh family member PTCH1. 
Interestingly, the c-MYC 3’UTR also harbors a miR-203 binding site, albeit poorly 
conserved. 3’UTR-based luciferase reporter assays subsequently demonstrated that all 
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genes identified were indeed regulated by miR-203. Moreover, cell-cycle analysis of 
primary keratinocytes transfected with miR-203 mimic oligonucleotides revealed a clear 
obstruction in the G1 to S-phase transition of the cell cycle. Immunohistochemical (IHC) 
analyses of these targets in BCC tumors confirmed substantial increases of protein 
expression when compared to healthy skin. Furthermore, IHC analyses in skin collected 
from the transgenic K5-TreGli1 mouse (which develop skin tumors closely resembling 
human BCCs) corroborated our findings in human tumors: BCC tumors consistently 
exhibit severely reduced expression of miR-203, which dramatically influences  the 
expression of genes involved in the regulation of cell proliferation and cell cycle, 
including key constituents of the Hh pathway (figure 6). 
Figure 6. A proposed autoregulatory loop involving the Hedgehog (Hh) and MAPK pathways, the 
proto-oncogens c-JUN and c-MYC, and the bona fide tumor supressor miR-203. See text for 
details. 
  
 In physiological settings, Hh signaling is required for the proliferation of hair follicle 
epithelium during development (Chiang et al., 1999; St-Jacques et al., 1998) and 
postnatal hair cycles, which include a growth phase (anagen), regression phase 
(catagen), and resting phase (telogen) (Wang et al., 2000). While Hh signaling activity in 
follicle epithelium is restricted to periods of active growth and is limited by transient 
levels of Sonic hedgehog (SHH), this pathway is constitutively active in BCCs. Recently, 
it was demonstrated that BCCs arise from long-lived progenitor cells residing in the 
interfollicular epidermis (IFE), a stem-cell containing compartment that can give rise to 
all epidermal lineages in response to appropriate stimuli (Owens and Watt, 2003; 
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Youssef et al., 2010). Importantly, like other cell lineages of the mammalian epidermis, 
IFE stem cells respond to Hh signaling, which results in de novo hair follicle formation 
(Silva-Vargas et al., 2005). As BCC tumors have several characteristics in common with 
immature hair follicles (i.e. stem-cell properties), including similar histology, 
ultrastructure, and gene expression patterns, it has been proposed that BCC tumors 
(and other tumors) reflect aberrant organogenesis caused by defects in developmental 
signaling pathways, such as Hh (Hutchin et al., 2005; Millar, 2002). In this respect, the 
gradient-like expression pattern of miR-203 in the suprabasal layers of the epidermis 
may serve as a molecular barrier to limit proliferative cues in replenishing skin. The loss 
of miR-203 in BCC may thus facilitate the inappropriate activation of Hh signaling, 
causing the reiteration of molecular programs normally regulating skin and hair 
development and ultimately leading to tumors which phenotypically resemble 
immature hair follicles. 
 In conclusion, our study represents the first analysis of miRNA expression and 
function in a non-melanoma skin cancer. The loss of miR-203 in BCC suggests that this 
miRNA could be used as a biomarker of the disease and may represent a potential 
therapeutic target for the treatment of BCC, especially for the rare cases of metastatic, 
locally advanced BCCs where surgical treatment options are limited. Further 
investigation will be needed to demonstrate whether the molecular reconstitution of 
miR-203 may serve as a novel therapeutic strategy in the treatment of BCC tumors. 
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4. CONCLUDING REMARKS
 
 
C O N S I D E R I N G  T H E  F U N D A M E N T A L  role of miRNAs in organismal development, 
cellular differentiation, metabolism, viral infection, and oncogenesis, the future of 
miRNA-based therapeutics holds great potential. In 2008, Elmén et al. demonstrated 
potent antagonism of miR-122 by the simple delivery of a unconjugated high-affinity 
LNA-antimiR oligonucleotide in mice and non-human primates (Elmen et al., 2008), 
providing a new molecular intervention strategy to target hepatitis C virus (HCV) in 
humans (Jopling et al., 2005). Moreover, the systemic administration of miR-26a in a 
mouse model of hepatocellular carcinoma (HCC) using adeno-associated virus (AAV) 
led to induction of tumor-specific apoptosis and dramatic protection from disease 
progression without measurable toxicity (Kota et al., 2009). Very recently, the first 
mechanistic evidence of RNAi in humans from an administered siRNA was 
demonstrated, verifying that RNAi can be used as a gene-specific therapeutic in human 
solid tumors (Davis et al., 2010). Together, these studies offer reassuring evidence that 
RNAi-based technologies are feasible in clinical settings and represent toxilogically 
sound approaches, with sparingly few side-effects reported so far (Bonetta, 2009).  To 
conclude, the work provided herein has identified new miRNA targets that may be 
exploited therapeutically to treat childhood and adult malignancies. While delivery and 
specificity remain a challenge for many diseases, especially for cancer, these issues will 
hopefully be resolved at the same rapid pace as the field of RNAi research has developed 
in the last few years. The future looks bright. 
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